Evidence for Gender-Specific Transcriptional Profiles of Nigral Dopamine Neurons in Parkinson Disease

Background Epidemiological data suggest that the male gender is one of the risks factors for the development of Parkinson Disease (PD). Also, differences in the clinical manifestation and the course of PD have been observed between males and females. However, little is known about the molecular aspects underlying gender-specificity in PD. To address this issue, we determined the gene expression profiles of male and female dopamine (DA) neurons in sporadic PD. Methodology/Principal Findings We analyzed Affymetrix-based microarrays on laser microdissected DA neurons from postmortem brains of sporadic PD patients and age-matched controls across genders. Pathway enrichment demonstrated that major cellular pathways involved in PD pathogenesis showed different patterns of deregulation between males and females with more prominent downregulation of genes related to oxidative phosporylation, apoptosis, synaptic transmission and transmission of nerve impulse in the male population. In addition, we found upregulation of gene products for metabolic processes and mitochondrial energy consumption in the age-matched male control neurons. On the single cell level, selected data validation using quantitative Real-Time (qRT)-PCR was consistent with microarray raw data and supported some of the observations from data analysis. Conclusions/Significance On the molecular level, our results provide evidence that the expression profiles of aged normal and PD midbrain DA neurons are gender-specific. The observed differences in the expression profiles suggest a disease bias of the male gender, which could be in concordance with clinical observations that the male gender represents a risk factor for sporadic PD. Validation of gene expression by qRT-PCR supported the microarray results, but also pointed to several caveats involved in data interpretation.

[1]  E. Perry,et al.  Cholinergic and other neurotransmitter mechanisms in Parkinson's disease, Parkinson's disease dementia, and dementia with Lewy bodies , 2007, Movement disorders : official journal of the Movement Disorder Society.

[2]  L. Martin,et al.  Motor neuron degeneration in amyotrophic lateral sclerosis mutant superoxide dismutase‐1 transgenic mice: Mechanisms of mitochondriopathy and cell death , 2007, The Journal of comparative neurology.

[3]  B. Kaspar,et al.  Gene-targeted therapies for the central nervous system. , 2008, Archives of neurology.

[4]  E. Hirsch,et al.  Role of activity‐dependent mechanisms in the control of dopaminergic neuron survival , 2007, Journal of neurochemistry.

[5]  N. Wood,et al.  Molecular basis of Parkinson's disease. , 2009, Neuroreport.

[6]  Xiao-hong Cai,et al.  Potassium channels: possible new therapeutic targets in Parkinson's disease. , 2008, Medical hypotheses.

[7]  Nobutaka Hattori,et al.  Prognosis of Parkinson's disease: Time to stage III, IV, V, and to motor fluctuations , 2006, Movement disorders : official journal of the Movement Disorder Society.

[8]  PINK1 Protects against Oxidative Stress by Phosphorylating Mitochondrial Chaperone TRAP1 , 2007, PLoS biology.

[9]  R. Stephens,et al.  SLEPR: A Sample-Level Enrichment-Based Pathway Ranking Method — Seeking Biological Themes through Pathway-Level Consistency , 2008, PloS one.

[10]  K. Lim,et al.  Protein misfolding and aggregation in Parkinson's disease. , 2009, Antioxidants & redox signaling.

[11]  J. Downing,et al.  Murine Leukemias with Retroviral Insertions at Lmo2 Are Predictive of the Leukemias Induced in SCID-X1 Patients Following Retroviral Gene Therapy , 2009, PLoS genetics.

[12]  Wei Jiang,et al.  Parkin, PINK1, and DJ-1 form a ubiquitin E3 ligase complex promoting unfolded protein degradation. , 2009, The Journal of clinical investigation.

[13]  J. Connor,et al.  Analysis of ferritin genes in Parkinson disease. , 2007, Clinical chemistry and laboratory medicine.

[14]  D. Berg,et al.  Disturbance of iron metabolism in Parkinson’s disease — ultrasonography as a biomarker , 2009, Neurotoxicity Research.

[15]  R. Stephens,et al.  Chromatin-Associated Genes Protect the Yeast Genome From Ty1 Insertional Mutagenesis , 2008, Genetics.

[16]  Christine A. Wells,et al.  A Cross-Study Transcriptional Analysis of Parkinson's Disease , 2009, PloS one.

[17]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[18]  Lorene M Nelson,et al.  Incidence of Parkinson's disease: variation by age, gender, and race/ethnicity. , 2003, American journal of epidemiology.

[19]  D. Burn Sex and Parkinson’s disease: a world of difference? , 2007, Journal of Neurology Neurosurgery & Psychiatry.

[20]  Martyn N J Paley,et al.  MRI assessment of basal ganglia iron deposition in Parkinson's disease , 2008, Journal of magnetic resonance imaging : JMRI.

[21]  D. Twelves,et al.  Systematic review of incidence studies of Parkinson's disease , 2003, Movement disorders : official journal of the Movement Disorder Society.

[22]  Michel Goedert,et al.  Tau protein and neurodegeneration. , 2004, Seminars in cell & developmental biology.

[23]  R. Stephens,et al.  Differences in the Tumor Microenvironment between African-American and European-American Breast Cancer Patients , 2009, PloS one.

[24]  Sonja W. Scholz,et al.  Genome-wide genotyping in Parkinson's disease and neurologically normal controls: first stage analysis and public release of data , 2006, The Lancet Neurology.

[25]  Y. Gupta,et al.  Status of antioxidant defense system and expression of toxicant responsive genes in striatum of maneb- and paraquat-induced Parkinson's disease phenotype in mouse: Mechanism of neurodegeneration , 2006, Brain Research.

[26]  J. Growdon,et al.  Molecular markers of early Parkinson's disease based on gene expression in blood , 2007, Proceedings of the National Academy of Sciences.

[27]  H. Braak,et al.  Invited Article: Nervous system pathology in sporadic Parkinson disease , 2008, Neurology.

[28]  Houeto Jean-Luc [Parkinson's disease]. , 2022, La Revue du praticien.

[29]  S. Leurgans,et al.  Genetic polymorphisms in Parkinson disease subjects with and without hallucinations: an analysis of the cholecystokinin system. , 2004, Archives of neurology.

[30]  G. Wooten,et al.  Are men at greater risk for Parkinson’s disease than women? , 2004, Journal of Neurology, Neurosurgery & Psychiatry.

[31]  R. Stephens,et al.  Genomic profiling of microRNA and messenger RNA reveals deregulated microRNA expression in prostate cancer. , 2008, Cancer research.

[32]  Robyn L Prueitt,et al.  Tumor immunobiological differences in prostate cancer between African-American and European-American men. , 2008, Cancer research.

[33]  Wolfgang Wurst,et al.  Fate of Midbrain Dopaminergic Neurons Controlled by the Engrailed Genes , 2001, The Journal of Neuroscience.

[34]  R. E. Burke Programmed cell death and new discoveries in the genetics of parkinsonism , 2008, Journal of neurochemistry.

[35]  M. Quik,et al.  Nicotinic receptors as CNS targets for Parkinson's disease. , 2007, Biochemical pharmacology.

[36]  C. Wilhelm,et al.  Different Microtubule Motors Move Early and Late Endocytic Compartments , 2008, Traffic.

[37]  X. Su,et al.  Genome-Wide Compensatory Changes Accompany Drug- Selected Mutations in the Plasmodium falciparum crt Gene , 2008, PloS one.

[38]  M. Mattson,et al.  Mitochondria in Neuroplasticity and Neurological Disorders , 2008, Neuron.

[39]  John N Weinstein,et al.  A stromal gene signature associated with inflammatory breast cancer , 2008, International journal of cancer.

[40]  M. Elstner,et al.  Individual dopaminergic neurons show raised iron levels in Parkinson disease , 2007, Neurology.

[41]  D. Surmeier,et al.  Calcium, ageing, and neuronal vulnerability in Parkinson's disease , 2007, The Lancet Neurology.

[42]  J. A. Cook,et al.  Heterogeneity in male to female risk for Parkinson’s disease , 2007, Journal of Neurology, Neurosurgery & Psychiatry.

[43]  D. Stephan,et al.  A survey of genetic human cortical gene expression , 2007, Nature Genetics.

[44]  L. Moran,et al.  Analysis of alpha-synuclein, dopamine and parkin pathways in neuropathologically confirmed parkinsonian nigra , 2007, Acta Neuropathologica.

[45]  C. Ríos,et al.  Free Copper, Ferroxidase and SOD1 Activities, Lipid Peroxidation and NOx Content in the CSF. A Different Marker Profile in Four Neurodegenerative Diseases , 2008, Neurochemical Research.

[46]  Benjamin W. H. Lim,et al.  Regulation of the GABA cell phenotype in hippocampus of schizophrenics and bipolars , 2007, Proceedings of the National Academy of Sciences.

[47]  Mostafa Ronaghi,et al.  Whole genome survey of coding SNPs reveals a reproducible pathway determinant of Parkinson disease , 2008, Human mutation.

[48]  G. Mellick CYP450, genetics and Parkinson's disease: gene x environment interactions hold the key. , 2006, Journal of neural transmission. Supplementum.

[49]  R. Uitti,et al.  Defining the Parkinson's disease phenotype: initial symptoms and baseline characteristics in a clinical cohort. , 2005, Parkinsonism & related disorders.

[50]  R. Stephens,et al.  Altered Gene Expression Profiles Define Pathways in Colorectal Cancer Cell Lines Affected by Celecoxib , 2008, Cancer Epidemiology Biomarkers & Prevention.

[51]  T. Gasser,et al.  DJ-1 and prevention of oxidative stress in Parkinson's disease and other age-related disorders. , 2009, Free radical biology & medicine.

[52]  R. Krüger,et al.  Review: Familial Parkinson's disease – genetics, clinical phenotype and neuropathology in relation to the common sporadic form of the disease , 2008, Neuropathology and applied neurobiology.

[53]  F Vaglini,et al.  Cytochrome P450 and Parkinson's disease: protective role of neuronal CYP 2E1 from MPTP toxicity. , 2006, Journal of neural transmission. Supplementum.

[54]  George A. Calin,et al.  Expression of microRNAs and protein‐coding genes associated with perineural invasion in prostate cancer , 2008, The Prostate.

[55]  R. Tyndale,et al.  Nicotine induces brain CYP enzymes: relevance to Parkinson's disease. , 2006, Journal of neural transmission. Supplementum.

[56]  Fang Yang,et al.  MPP+ impairs autophagic clearance of alpha-synuclein by impairing the activity of dynein , 2009, Neuroreport.

[57]  Mariza de Andrade,et al.  High-resolution whole-genome association study of Parkinson disease. , 2005, American journal of human genetics.

[58]  Ming Yi,et al.  Seeking unique and common biological themes in multiple gene lists or datasets: pathway pattern extraction pipeline for pathway-level comparative analysis , 2009, BMC Bioinformatics.

[59]  M. Frosch,et al.  Effects of gender on nigral gene expression and parkinson disease , 2007, Neurobiology of Disease.

[60]  M. Delong,et al.  Prevalence of vitamin d insufficiency in patients with Parkinson disease and Alzheimer disease. , 2008, Archives of neurology.

[61]  K. Doheny,et al.  Genomewide association study for susceptibility genes contributing to familial Parkinson disease , 2009, Human Genetics.

[62]  Bastiaan R Bloem,et al.  Gender differences in Parkinson’s disease , 2006, Journal of Neurology, Neurosurgery & Psychiatry.

[63]  Andrew B West,et al.  Molecular pathophysiology of Parkinson's disease. , 2005, Annual review of neuroscience.

[64]  F. Benes,et al.  Gene expression profiling of substantia nigra dopamine neurons: further insights into Parkinson's disease pathology. , 2009, Brain : a journal of neurology.

[65]  T. Nagatsu [Biochemistry of Parkinson's disease]. , 1988, Seikagaku. The Journal of Japanese Biochemical Society.